Tamoxifen Citrate

Catalog No.S1972 Synonyms: ICI 46474 Citrate

Tamoxifen Citrate Chemical Structure

Molecular Weight(MW): 563.64

Tamoxifen Citrate is an antagonist of the estrogen receptor by competitive inhibition of estrogen binding.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 1 Publication

1 Customer Review

  • Effects of DPN, LY500307, Raloxifene and Tamoxifen on cell viability in BSO-treated FRDA fibroblasts. BSO concentration was 1 mM and all steroid concentrations were 100 nM. Depicted are mean ± SD for n= 8 per group. * indicated p<0.05 versus BSO alone-treated cells.

    University of North Texas Health Science Center, 2014.. Tamoxifen Citrate purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Tamoxifen Citrate is an antagonist of the estrogen receptor by competitive inhibition of estrogen binding.
Targets
ER [1]
(Cell-free assay)
In vitro

Tamoxifen displays antitumor effect due to its antiestrogenic activity (ER). Values for the apparent affinity of Tamoxifen for the ER range between 30 and 0.01% of that obtained for estradiol, dependent on different ER source (species), protein concentration and condition used for assay. Binding of Tamoxifen to ER further leads to inhibition expression of estrogen-regulated genes, including growth factors and angiogenic factors secreted by the tumor that may stimulate growth by autocrine or paracrine mechanisms. Tamoxifen also directly induces programmed cell death. [1] Tamoxifen produces an inhibitory effect on MCF-7 cell [3H]thymidine incorporation and DNA polymerase activity as well as causing a reduction in DNA content of cultures and cell numbers. This inhibitory effect of Tamoxifen on MCF-7 cell growth can be readily reversed by addition of estradiol to the culture medium. 2 and 6 μM Tamoxifen reduces the proportion of cells in S phase and increases the number of cells in G1. At 10 μM, Tamoxifen causes cell death within 48 hr. [2] Tamoxifen inhibits MCF-7 growth with IC50 of ~10 nM after 10 days treatment. Tamoxifen inhibits plasminogen activator activity of MCF-7, and suppresses estradiol-stimulation of plasminogen activator activity. Tamoxifen also evokes minimal increases in cellular progesterone receptor levels. [3] Tamoxifen is able to inhibit the growth of prostate cancer cell PC3, PC3-M, and DU145 with IC50 ranged from 5.5-10 μM, which is related to its inhibition of protein kinase C and induction of p21(waf1/cip1). [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MCF7 cells Ml\yR5l1d3SxeHnjxsBie3OjeR?= NWToSoluOThiaB?= MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEG4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUCuNkDPxE1? MXWxPVk{OjB{NB?=
human MDA-MB-231 cells NULCSFAyS3m2b4TvfIlkyqCjc4PhfS=> MW[xPEBp NYP3NXpES3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjCxPEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGyMlMh|ryP NHzqUHgyQTl|MkCyOC=>
human Ishikawa cells M4jKd2N6fG:2b4jpZ:Kh[XO|YYm= MUixPEBp MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDJd4hqc2G5YTDj[YxteyCjZoTldkAyQCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEzNjVizszN NHjQR5YyQTl|MkCyOC=>
human DU145 cells Mm\NR5l1d3SxeHnjxsBie3OjeR?= M1jDS|E5KGh? NHfESoJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjZoTldkAyQCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE2NjJ3IN88US=> NHTIfIgyQTl|MkCyOC=>

... Click to View More Cell Line Experimental Data
In vivo Tamoxifen administration to rapidly growing, estradiol-stimulated MCF-7 xenografts results in a dose-dependent retardation or cessation of tumor growth by significantly decreasing tumor cell proliferation in tumor. Tamoxifen treatment results in a slowing of tumor growth (tumor doubling time, 12 days), a significant increase in tumor potential doubling time (Tpot) (6.6 days), and a decrease in labeling index (%LI) (to 8%) by 23 days posttreatment, compared with untreated mice which shows a volume doubling time of 5 days, a Tpot of 2.3 days, and a %LI of 23%. [5] Tamoxifen has not only antiestrogenic but also estrogenic properties depending on the species, tissue, and gene. Tamoxifen displays favorable effects on bone and serum lipid concentrations and stimulation endometrium. [1]

Protocol

Kinase Assay:

[3]
+ Expand

Competitive binding assays:

Cells are harvested from 150-sq cm T-flasks, and cytosol is prepared at a protein concentration of approximately 2 mg/mL in phosphate buffer. Aliquots of this 180,000 ×g supernatant are then incubated with various concentrations of Tamoxifen and 2.5 nM [3H]estradiol for 16 hr at 0-4 ℃. The free steroids are absorbed by dextran-charcoal [l0 μL of 0.5% Dextran C-5% Norite A in TE buffer] for 1 hr at 0 ℃, and aliquots are counted after centrifugation at 800 ×g, 30 min. The relative binding ability of each competitor is taken as the ratio of the concentration of radioinert estradiol/competitor required to inhibit one-half of the specific [3H]estradiol binding, with the affinity of estradiol set at 100%.
Cell Research:

[3]
+ Expand
  • Cell lines: Human breast cancer cells MCF-7
  • Concentrations: ~1 μM
  • Incubation Time: 10 days
  • Method:

    MCF-7 cells are seeded into T-25 flasks (1.5×105 cells/flask) and grown for 2 days in the MEM supplemented with 10 mM HEPES buffer, gentamicin (50 μg/mL), penicillin (100 units/mL), streptomycin (0.1 mg/mL), bovine insulin (6 ng/mL), hydrocortisone (3.75 ng/mL), and 5% calf serum that has been treated with dextran-coated charcoal for 45 min at 55 ℃ to remove endogenous hormones. The medium is then changed to MEM supplemented as described above, except that it contains 2% charcoal dextran-treated calf serum and various concentrations of Tamoxifen. At the end of incubation, cell numbers are counted.


    (Only for Reference)
Animal Research:

[5]
+ Expand
  • Animal Models: Human breast carcinoma xenografts MCF-7
  • Formulation: Silastic capsules
  • Dosages: 2 cm Tamoxifen capsules
  • Administration: Subcutaneous implantation
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (177.41 mM)
Ethanol 100 mg/mL (177.41 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing. 		30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 563.64
Formula

C26H29NO.C6H8O7
CAS No. 54965-24-1
Storage powder
in solvent
Synonyms ICI 46474 Citrate

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03879174 Not yet recruiting Breast Cancer Female Mediclinic Middle East August 1 2019 Phase 2
NCT03879174 Not yet recruiting Breast Cancer Female Mediclinic Middle East August 1 2019 Phase 2
NCT03879577 Not yet recruiting Breast Cancer|Breast Cancer Female|HER2-positive Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III University of Chicago April 10 2019 Phase 2
NCT03879577 Not yet recruiting Breast Cancer|Breast Cancer Female|HER2-positive Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III University of Chicago April 10 2019 Phase 2
NCT03870399 Recruiting Neuroendocrine Tumors|Progesterone Receptor Positive Tumor|Estrogen Receptor Positive Tumor AC Camargo Cancer Center March 13 2019 Phase 2
NCT03870399 Recruiting Neuroendocrine Tumors|Progesterone Receptor Positive Tumor|Estrogen Receptor Positive Tumor AC Camargo Cancer Center March 13 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am wondering if the Tamoxifen (product Cat # S1972) is a 4-hydroxy Tamoxifen form or just plain Tamoxifen Citrate?

  • Answer:

    The Tamoxifen (S1972) is a prodrug, just plain Tamoxifen citrate.

selleck catalog

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

  • Selective AR agonist

    Andarine : Selective non-steroidal AR agonist, Ki=4 nM.

  • Most Potent AR Antagonist

    ARN-509 : Androgen receptor, IC50=16 nM.

  • FDA-approved AR Antagonist

    Bicalutamide : Approved by FDA for prostate cancer.

  • Newest AR Antagonist

    AZD3514 : Potent and oral androgen receptor downregulator with Ki of 2.2 μM.

Related Estrogen/progestogen Receptor Products4

  • Licochalcone A New

    Licochalcone A is an estrogenic flavanoid extracted from licorice root, showing antimalarial, anticancer, antibacterial and antiviral activities. Phase 3.

  • Endoxifen HCl New

    Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.

  • Sacubitril/valsartan (LCZ696) New

    Sacubitril/valsartan (LCZ696), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.

  • Fulvestrant

    Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

  • Mifepristone

    Mifepristone is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively.

    Features:Mifepristone is the first approved medication for patients with endogenous cushing's syndrome.

  • Raloxifene HCl

    Raloxifene is an estrogen antagonist, which inhibits human cytosolic aldehyde oxidase-catalyzed phthalazine oxidation activity with IC50 of 5.7 nM.

    Features:Raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk.

  • Estradiol

    Estradiol, or more precisely, 17β-estradiol, is a human sex hormone and steroid, and the primary female sex hormone.

  • Toremifene Citrate

    Toremifene Citrate is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.

  • Progesterone

    Progesterone is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR) with Kd of 1 nM; An agonist of the membrane progesterone receptors(mPRs); An antagonist of the σ1 receptor.

  • Bazedoxifene HCl

    Bazedoxifene HCl is a novel, non-steroidal, indole-based estrogen receptor modulator (SERM) binding to both ERα and ERβ with IC50 of 23 nM and 89 nM, respectively.

Tags: buy Tamoxifen Citrate | Tamoxifen Citrate ic50 | Tamoxifen Citrate price | Tamoxifen Citrate cost | Tamoxifen Citrate solubility dmso | Tamoxifen Citrate purchase | Tamoxifen Citrate manufacturer | Tamoxifen Citrate research buy | Tamoxifen Citrate order | Tamoxifen Citrate mouse | Tamoxifen Citrate chemical structure | Tamoxifen Citrate mw | Tamoxifen Citrate molecular weight | Tamoxifen Citrate datasheet | Tamoxifen Citrate supplier | Tamoxifen Citrate in vitro | Tamoxifen Citrate cell line | Tamoxifen Citrate concentration | Tamoxifen Citrate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID